Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SMMTthis companySummit Therapeutics Inc.	$17.76	-12.15×	26.74×	0×	-11.97×	-98.4%	0.0%	0.0%	0.0%	-220.8%	-216.3%	-1.8%	0.03×	0.14×	0×	9.87×	0.0%	2	39.13	2	C
ACXPAcurx Pharmaceuticals, Inc.	$1.08	-0.47×	0.71×	0×	0.48×	374.0%	0.0%	0.0%	0.0%	-151.2%	-153.6%	-181.9%	0×	0.95×	0×	3.18×	0.0%	2	-10.22	2	B-
ENTAEnanta Pharmaceuticals, Inc.	$11.46	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
IBRXImmunityBio, Inc.	$7.01	-5.21×	-3.65×	16.08×	-11.68×	-355.9%	99.3%	-226.0%	-310.2%	70.3%	-56.9%	-17.0%	-1.76×	-3.53×	-2.28×	5.1×	0.0%	3	-10.89	2	C
MCRBSeres Therapeutics, Inc.	$2.00	23.25×	2.98×	167.07×	17.2×	-266.7%	-423.8%	-11910.1%	721.9%	12.9%	-72.7%	0.7%	1.88×	3.78×	0×	2.56×	0.0%	3	-14.74	1	C-
PALIPalisade Bio, Inc.	$1.23	-7.83×	1.01×	0×	0.15×	113.1%	0.0%	0.0%	0.0%	-13.0%	-13.9%	-8.3%	0×	7.95×	-1,805.6×	28.95×	0.0%	4	19.43	2	C
Peer median	—	-3.12×	1.01×	3.91×	0.15×	-266.7%	0.0%	-130.7%	0.0%	-13.0%	-56.9%	-12.6%	0×	0.95×	-2.28×	4.21×	0.0%	3	-10.22	2	—